Tybourne Capital Management Limited is a principal investment firm that focuses on public and private equity markets. Established in 2010 and headquartered in Hong Kong, the firm also maintains an office in San Francisco, California. Tybourne employs a fundamental approach to equity investing, targeting growth and expansion opportunities in various sectors. Its global perspective allows it to navigate diverse markets effectively, making it a notable player in the investment landscape.
Forte Biosciences is a biotechnology company specializing in dermatology and biopharmaceuticals. The company's lead product, FB-401, is a topically applied live biotherapeutic designed to treat inflammatory skin diseases, developed in collaboration with the National Institutes of Health and the National Institute of Allergy and Infectious Diseases. Additionally, Forte Biosciences is advancing another product candidate, FB-102, which is a proprietary therapeutic molecule aimed at addressing a range of autoimmune conditions, including graft-versus-host disease, vitiligo, and alopecia areata. The company is currently in the preclinical trial stage for FB-102, reflecting its commitment to developing innovative treatments for dermatological and autoimmune disorders.
SkyCell
Series D in 2024
SkyCell AG specializes in designing and manufacturing temperature-controlled containers tailored for the pharmaceutical industry. Founded in 2013 and headquartered in Zurich, Switzerland, the company focuses on ensuring the safe transport of temperature-sensitive goods. Its product lineup includes various models such as SkyCell 2500C, SkyCell 2500CRT, SkyCell 1500C, SkyCell 1500CRT, SkyCell 770C, and SkyCell 770CRT. Equipped with Internet of Things (IoT) sensors, these containers connect to SkyCell's data cloud, enabling real-time monitoring and intervention to prevent temperature excursions. Additionally, the company's software leverages blockchain technology to enhance tracking and visibility throughout the supply chain. SkyCell is committed to sustainability and reducing carbon emissions while addressing logistical challenges faced by global pharmaceutical companies.
Forte Biosciences
Post in 2023
Forte Biosciences is a biotechnology company specializing in dermatology and biopharmaceuticals. The company's lead product, FB-401, is a topically applied live biotherapeutic designed to treat inflammatory skin diseases, developed in collaboration with the National Institutes of Health and the National Institute of Allergy and Infectious Diseases. Additionally, Forte Biosciences is advancing another product candidate, FB-102, which is a proprietary therapeutic molecule aimed at addressing a range of autoimmune conditions, including graft-versus-host disease, vitiligo, and alopecia areata. The company is currently in the preclinical trial stage for FB-102, reflecting its commitment to developing innovative treatments for dermatological and autoimmune disorders.
Clove Dental
Series D in 2022
Clove Dental operates a network of multi-specialty dental clinics that provide a wide range of professional oral healthcare services. With over 350 clinics and a patient base exceeding 1 million each month, Clove Dental specializes in various treatments including endodontics, periodontics, orthodontics, prosthodontics, cosmetic dentistry, pediatric care, and oral and maxillofacial surgery. The company is committed to high standards of hygiene, clinic safety, and customer service, employing more than 800 dentists and utilizing advanced equipment and pain-management technologies to enhance patient experiences.
Asuene
Series B in 2022
Asuene is a company focused on renewable power retail services that facilitate local production and consumption of energy. Additionally, it has developed a carbon management platform aimed at assisting organizations in tracking, managing, and reporting their greenhouse gas emissions and other environmental impacts. Utilizing artificial intelligence, the platform integrates various data sources to collect emissions information and formulate strategies for reducing pollutants over time. This enables organizations to effectively manage their environmental footprint, comply with regulatory requirements, and work towards their sustainability objectives.
Acelyrin
Series C in 2022
Acelyrin is a late-stage clinical biopharmaceutical company dedicated to advancing new treatment options for patients. The company specializes in identifying, acquiring, and accelerating the development and commercialization of promising drug candidates. By leveraging its expertise, Acelyrin aims to rapidly bring transformative medicines to market, ultimately improving patient outcomes and quality of life.
Kopi Kenangan
Series C in 2021
Kopi Kenangan is one of several grab-and-go coffee chains trying to capitalize on the rising trend and demand for grounded coffee beverages in a country which has the lowest coffee consumption per capita in the region, despite being the world’s fourth-largest coffee exporter.
Lunit
Venture Round in 2021
Lunit Inc. is a medical AI software company based in Seoul, South Korea, specializing in advanced algorithms for medical image analysis and general object detection. The company focuses on developing solutions that aid physicians in making objective diagnoses through machine learning technology. Lunit's expertise encompasses various medical imaging fields, including digital chest X-ray, digital mammography, digital pathology, and fundus photography. The company's products include Lunit INSIGHT CXR for chest X-rays, Lunit INSIGHT MMG for mammography, and Lunit SCOPE, which provides AI-powered biomarkers for immuno-oncology. Lunit aims to enhance clinical decision-making by leveraging data-driven imaging biomarker technology, ultimately improving the accuracy and efficiency of cancer care. The effectiveness of Lunit's deep learning technology has been validated through its recognition in major image recognition competitions, showcasing its capacity to process complex medical imaging data.
Acelyrin
Series B in 2021
Acelyrin is a late-stage clinical biopharmaceutical company dedicated to advancing new treatment options for patients. The company specializes in identifying, acquiring, and accelerating the development and commercialization of promising drug candidates. By leveraging its expertise, Acelyrin aims to rapidly bring transformative medicines to market, ultimately improving patient outcomes and quality of life.
Caddi
Series B in 2021
Caddi, Inc. is a technology company based in Tokyo, Japan, that specializes in providing solutions for the manufacturing sector. It operates an online ordering platform that facilitates the management of custom-made processed products and connects orders with processing plants. By utilizing a proprietary costing algorithm, the platform automatically identifies the most suitable factory for production, thereby helping businesses to reduce procurement costs and optimize quality, cost, and delivery (QCD). Additionally, Caddi offers an AI-driven data platform that enhances procurement intelligence and supply chain management, enabling companies to improve operational efficiency and expand their capacity.
Zentera Therapeutics
Series B in 2021
Zentera Therapeutics is a biopharmaceutical company.
Amylyx Pharmaceuticals
Series C in 2021
Amylyx Pharmaceuticals develops innovative therapies for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. The company's primary product, AMX0035, is an investigational therapy that combines two active compounds, sodium phenylbutyrate and Taurursodiol. This fixed-dose formulation aims to address mitochondrial energy crises and the accumulation of toxic proteins in the endoplasmic reticulum, which contribute to neurological decline. In addition to ALS, Amylyx's research pipeline includes potential treatments for Wolfram syndrome and Alzheimer's disease. Founded in 2013 and based in Cambridge, Massachusetts, Amylyx Pharmaceuticals is dedicated to advancing solutions for serious brain disorders.
Wugen
Series B in 2021
Wugen is focused on developing off-the-shelf cellular therapies for cancer, particularly utilizing natural killer (NK) cells and CAR-T cell therapies. The company enhances NK cells obtained from healthy donors to improve their ability to target and eliminate cancer cells. Wugen's innovative approach includes a proprietary platform that leverages advanced genomic engineering to create next-generation memory NK cell therapies. These therapies specifically aim to address various types of malignancies, including solid tumors, acute myeloid leukemia, and T-cell malignancies, thereby providing new treatment options for patients facing life-threatening cancers.
Paidy
Series D in 2021
Paidy Inc. is a Tokyo-based company established in 2008, specializing in a cardless real-time payment network that simplifies online transactions for consumers. Formerly known as Exchange Corporation K.K., the company rebranded in 2018 to reflect its focus on providing an efficient payment solution that does not require credit cards or pre-registration. Paidy's software platform allows users to make purchases online and pay for them through a consolidated monthly bill, leveraging proprietary technology to assess creditworthiness and guarantee payments to merchants. This approach caters particularly to Japanese consumers, many of whom prefer avoiding credit cards for online shopping. By facilitating cardless payments, Paidy helps eCommerce operators enhance their conversion rates, increase average order values, and boost repeat purchases.
Momo
Series D in 2021
Momo is a FinTech startup that provides a mobile electronic wallet and payment application for iOS and Android devices, primarily serving customers in Vietnam. The platform facilitates nationwide cash transfers, bill payments for over 100 types of services, mobile phone recharges, and personal loan settlements. Additionally, Momo enables users to purchase various services, including software licenses, online gaming cards, and tickets for airlines and movies. The company collaborates with 24 domestic banks and international payment networks, ensuring secure and efficient financial transactions for its users. Momo aims to simplify the payment experience, making it effortless and safe for individuals to manage their financial activities.
Provivi
Series C in 2020
Provivi Inc. specializes in developing biopesticides aimed at pest management in agriculture, commercial sectors, households, and public health. The company's innovative approach focuses on using insect pheromones, which provide a safe, environmentally friendly alternative to traditional pesticides. By leveraging biocatalysis technology initially developed at the California Institute of Technology, Provivi enhances the synthesis of these biopesticides, ensuring they are effective and free from toxic residues. Founded in 2013 and based in Santa Monica, California, the company collaborates with distributors worldwide to deliver its products, which are designed to protect food supplies sustainably and affordably. With a team of experienced professionals from biotechnology and the agricultural chemicals industry, Provivi is positioned to transform pest management practices through its advanced biological processes.
LianBio
Venture Round in 2020
LianBio is a biopharmaceutical company based in Shanghai, China, with an additional office in Princeton, New Jersey. Founded in 2019, the company focuses on the discovery and development of therapeutic drugs aimed at treating oncology and cardiorenal diseases, as well as other medical conditions. LianBio's mission is to enhance access to innovative medicines by partnering with leading organizations in the field to leverage advanced scientific discoveries. The company is dedicated to addressing unmet medical needs in Greater China and other Asian markets by in-licensing assets and building a diverse pipeline of clinically validated product candidates. Its portfolio aims to establish new standards of care across various therapeutic areas, including cardiovascular, oncology, ophthalmology, inflammatory diseases, and respiratory conditions.
Zentera Therapeutics
Series A in 2020
Zentera Therapeutics is a biopharmaceutical company.
Paidy
Series C in 2019
Paidy Inc. is a Tokyo-based company established in 2008, specializing in a cardless real-time payment network that simplifies online transactions for consumers. Formerly known as Exchange Corporation K.K., the company rebranded in 2018 to reflect its focus on providing an efficient payment solution that does not require credit cards or pre-registration. Paidy's software platform allows users to make purchases online and pay for them through a consolidated monthly bill, leveraging proprietary technology to assess creditworthiness and guarantee payments to merchants. This approach caters particularly to Japanese consumers, many of whom prefer avoiding credit cards for online shopping. By facilitating cardless payments, Paidy helps eCommerce operators enhance their conversion rates, increase average order values, and boost repeat purchases.
Provivi
Series C in 2019
Provivi Inc. specializes in developing biopesticides aimed at pest management in agriculture, commercial sectors, households, and public health. The company's innovative approach focuses on using insect pheromones, which provide a safe, environmentally friendly alternative to traditional pesticides. By leveraging biocatalysis technology initially developed at the California Institute of Technology, Provivi enhances the synthesis of these biopesticides, ensuring they are effective and free from toxic residues. Founded in 2013 and based in Santa Monica, California, the company collaborates with distributors worldwide to deliver its products, which are designed to protect food supplies sustainably and affordably. With a team of experienced professionals from biotechnology and the agricultural chemicals industry, Provivi is positioned to transform pest management practices through its advanced biological processes.
CarDekho
Series C in 2019
CarDekho provides enterprise mobility solutions, mobile application development, Web design and development, offshore staffing, and testing and quality assurance (QA) services. Its enterprise mobility solutions include enterprise mobility consulting, mobile business intelligence, business process mobilization, B2B mobile applications (app) development, enterprise iOS app development, enterprise Android app development, and enterprise app distribution; and mobile app development services include iPhone, iPad, Android, Blackberry, Windows8, Phonegap, and bootstrap. CarDekho’s Web design and development services include responsive design, PSD to HTML conversion, flash Website design, themes customization, content management system, E-commerce solution, CRM app development, open-source development, custom Web app development, regular Website maintenance, customized programming, online marketing, graphic design, Website hosting, employee management system, logo design, inventory management, and database design. Its offshore staffing services for designers, mobile apps developers,.NET developers, PHP developers, Java developers, Python developers, and ROR developers; and testing and QA services include automated, manual, usability, nonfunctional, specialized, mobile app, testing-as-a-service, integration, functional, system, localization, and acceptance testing. CarDekho develops entertainment, GPS tracking, weather, business and finance-related, multi-media, sports, social networking, education, and travel applications. It serves the automobile, E-learning, consultancy, finance, social networking, tours and travel, health and fitness, medical, job and career, news and magazine, utility/productivity, entertainment, lifestyle, and E-commerce industries; and IT and communication, and book and library industries.
Bicycle Therapeutics
Series B in 2018
Bicycle Therapeutics is a clinical-stage biopharmaceutical company focused on developing a novel class of medicines known as Bicycles, which are synthetic short peptides designed to stabilize their structural geometry through two loops. The company primarily targets oncology indications with significant unmet medical needs. Its lead product candidate, BT1718, is a Bicycle Toxin Conjugate currently undergoing Phase I/IIa clinical trials aimed at tumors expressing Membrane Type 1 matrix metalloprotease. Other oncology candidates include BT5528, also in Phase I/IIa trials targeting EphA2, and BT8009, which is in preclinical studies for Nectin-4. Additionally, Bicycle Therapeutics is developing THR-149, a plasma kallikrein inhibitor that has completed Phase I trials for diabetic macular edema. The company collaborates with various biopharmaceutical organizations to advance programs in areas like anti-infectives and cardiovascular health. Founded in 2009, Bicycle Therapeutics is headquartered in Cambridge, United Kingdom.
FreeCharge
Series C in 2015
FreeCharge is an e-commerce website headquartered in Mumbai, Maharashtra that provides online facility to recharge any prepaid mobile phone, postpaid mobile, DTH & data card in India. The website was started in August, 2010 by Kunal Shah of Accelyst Solutions Pvt. Ltd. In November 2012, the company claimed to be doing online recharge of INR 6 million on a daily basis, translating to INR 2.19 billion a year. It provides online facility to recharge any prepaid mobile phone in India. The amount paid by the user for recharge is returned in form of shopping coupons of some of the top retailers in India, thereby making the recharge virtually free. The first two retailers for which coupons were available were McDonald's and Barista. and were followed by other big retailers such as Café Coffee Day, Domino's Pizza, Cromā, Puma, Shoppers Stop and Jet Airways. In 2011, FreeCharge was named one of the most promising technology startups from India by Pluggd.in.
CarDekho
Series B in 2015
CarDekho provides enterprise mobility solutions, mobile application development, Web design and development, offshore staffing, and testing and quality assurance (QA) services. Its enterprise mobility solutions include enterprise mobility consulting, mobile business intelligence, business process mobilization, B2B mobile applications (app) development, enterprise iOS app development, enterprise Android app development, and enterprise app distribution; and mobile app development services include iPhone, iPad, Android, Blackberry, Windows8, Phonegap, and bootstrap. CarDekho’s Web design and development services include responsive design, PSD to HTML conversion, flash Website design, themes customization, content management system, E-commerce solution, CRM app development, open-source development, custom Web app development, regular Website maintenance, customized programming, online marketing, graphic design, Website hosting, employee management system, logo design, inventory management, and database design. Its offshore staffing services for designers, mobile apps developers,.NET developers, PHP developers, Java developers, Python developers, and ROR developers; and testing and QA services include automated, manual, usability, nonfunctional, specialized, mobile app, testing-as-a-service, integration, functional, system, localization, and acceptance testing. CarDekho develops entertainment, GPS tracking, weather, business and finance-related, multi-media, sports, social networking, education, and travel applications. It serves the automobile, E-learning, consultancy, finance, social networking, tours and travel, health and fitness, medical, job and career, news and magazine, utility/productivity, entertainment, lifestyle, and E-commerce industries; and IT and communication, and book and library industries.
GirnarSoft
Series B in 2015
Girnar Software (SEZ) Private Limited, founded in 2007, is a mobile and web solutions development company that specializes in software development. With a team of over 900 skilled engineers and management professionals, the company focuses on delivering comprehensive services, including product development, manual and automation testing, mobile application development, and custom software solutions. GirnarSoft also operates automotive portals and marketplaces, providing businesses with the tools to achieve their IT objectives and enhance overall value. The company is a member of prominent organizations such as the National Association of Software and Services Companies and the Software Technology Parks of India, further solidifying its commitment to quality and innovation in the software industry.
Snapdeal
Series E in 2014
Snapdeal is India's largest online marketplace, launched in February 2010, that connects buyers and sellers across a wide range of product categories including mobile phones, electronics, apparel, cosmetics, and home goods. The platform is designed to create a reliable and frictionless commerce ecosystem, offering convenient delivery options even to remote areas. Snapdeal is notable for its competitive pricing, featuring daily deals and discounts that make various products accessible to consumers. It has established itself as a market leader in the retail space and is recognized for its significant presence in categories such as watches, sunglasses, and jewelry. With over 1,000 employees, Snapdeal fosters a vibrant work environment and continues to play a critical role in India's e-commerce landscape.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.